IN2015DN03331A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03331A
IN2015DN03331A IN3331DEN2015A IN2015DN03331A IN 2015DN03331 A IN2015DN03331 A IN 2015DN03331A IN 3331DEN2015 A IN3331DEN2015 A IN 3331DEN2015A IN 2015DN03331 A IN2015DN03331 A IN 2015DN03331A
Authority
IN
India
Prior art keywords
sina
betahydroxysteroid
dchydrogenase
isd1
beta
Prior art date
Application number
Other languages
English (en)
Inventor
Antón Ana Isabel Jiménez
Angela Sesto Yague
GÓMEZ Ma Concepción JIMÉNEZ
Original Assignee
Sylentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sa filed Critical Sylentis Sa
Publication of IN2015DN03331A publication Critical patent/IN2015DN03331A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01146—11-Beta-hydroxysteroid dehydrogenase (1.1.1.146)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN3331DEN2015 2005-10-25 2006-10-25 IN2015DN03331A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0521716.1A GB0521716D0 (en) 2005-10-25 2005-10-25 Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
PCT/GB2006/050352 WO2007049074A2 (fr) 2005-10-25 2006-10-25 Modulation d'expression de 11 beta-hydroxysteroide deshydrogenase 1 pour le traitement de maladies oculaires

Publications (1)

Publication Number Publication Date
IN2015DN03331A true IN2015DN03331A (fr) 2015-10-23

Family

ID=35458653

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3331DEN2015 IN2015DN03331A (fr) 2005-10-25 2006-10-25

Country Status (12)

Country Link
US (1) US8188057B2 (fr)
EP (2) EP2354229A3 (fr)
JP (2) JP5398262B2 (fr)
CN (1) CN101346467B (fr)
AU (1) AU2006307690B2 (fr)
CA (1) CA2627272C (fr)
ES (1) ES2403305T3 (fr)
GB (1) GB0521716D0 (fr)
IN (1) IN2015DN03331A (fr)
MX (1) MX2008005409A (fr)
RU (1) RU2420582C2 (fr)
WO (1) WO2007049074A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049543A1 (en) * 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
WO2009073460A2 (fr) * 2007-12-03 2009-06-11 Bausch & Lomb Incorporated Inhibition de la 11 bêta-hydroxystéroïde déhydrogénase de type 1 pour une neuroprotection oculaire
CN101969282A (zh) * 2010-10-25 2011-02-09 北京印刷学院 抛物柱面聚光凹形闭合腔体采光太阳能发电装置
CN101976979A (zh) * 2010-10-25 2011-02-16 北京印刷学院 抛物柱面聚光半圆柱面闭合腔体采光太阳能发电装置
MX371518B (es) * 2013-09-13 2020-01-31 Ionis Pharmaceuticals Inc Moduladores del factor del complemento b.
MX2018002857A (es) * 2015-09-08 2018-09-12 Sylentis Sau Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp.
CN106702003B (zh) * 2017-02-28 2021-02-12 固安博健生物技术有限公司 Hsdl1在诊治骨肉瘤中的应用
CN109022436B (zh) * 2018-06-07 2021-04-09 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） 特异抑制3β-HSD基因表达的shRNA重组载体构建与应用
JP6617191B1 (ja) * 2018-12-03 2019-12-11 三井金属鉱業株式会社 溶液中の目的成分を分離又は分析するための方法及び装置
CN120204234B (zh) * 2025-05-28 2025-08-19 温州医科大学附属眼视光医院 11β-HSD1通路活性抑制剂在制备治疗青光眼睫状体炎综合征药物上的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
EP1147204A1 (fr) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
DE60130583T3 (de) 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie Kleine rns moleküle, die rns-interferenz vermitteln
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) * 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003059267A2 (fr) * 2001-12-21 2003-07-24 Rhode Island Hospital INHIBITEURS SELECTIFS DE 11β-HSD ET LEURS PROCEDES D'UTILISATION
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (fr) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Inhibition a mediation par interference d'arn de genes de map kinase
CA2482903A1 (fr) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Moyens et procedes pour l'inhibition specifique de genes dans les cellules et le tissu du systeme nerveux central et/ou de l'oeil
US20040115641A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
US20040146858A1 (en) 2002-07-24 2004-07-29 Immusol, Inc. Novel siRNA gene libraries and methods for their production and use
EP1554386A2 (fr) 2002-07-24 2005-07-20 Immusol Incorporated Systeme a un seul promoteur pour la production de cassettes d'expression d'arnsi et genotheque d'expression reposant sur l'utilisation d'un lieur en epingle a cheveux d'amorce de polymerase
MXPA05001355A (es) 2002-08-05 2005-09-30 Atugen Ag Formas nuevas adicionales de moleculas de arn de interferencia.
ATE513843T1 (de) 2002-09-25 2011-07-15 Univ Massachusetts Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
AU2003291678B2 (en) 2002-11-01 2009-01-15 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20050020550A1 (en) * 2003-04-29 2005-01-27 Morris David J. Selective testicular 11beta-HSD inhibitors and methods of use thereof
WO2004099372A2 (fr) 2003-05-01 2004-11-18 University Of Florida Ribozymes anti-cicatrisants et methodes associees
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
DE10322539A1 (de) 2003-05-19 2004-12-09 Siemens Ag Verfahren zum Aufbau einer Kommunikationsverbindung und Kommunikationssystem
WO2005044976A2 (fr) 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Composes oligomeres utilises pour la modulation de genes
WO2005034870A2 (fr) 2003-10-07 2005-04-21 Renovis, Inc. Composes amides et ligands de canaux ioniques, et leurs utilisations
KR20050039573A (ko) 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
WO2005045037A2 (fr) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Inhibition mediee par une interference arn de 5-alpha reductase et expression genique du recepteur d'androgenes faisant appel a un petit acide nucleique interferant (sina)
US20050208658A1 (en) * 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CN101052644A (zh) 2004-02-05 2007-10-10 因特拉迪格姆公司 治疗眼新生血管化疾病的RNAi治疗药物
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
EP2899278A1 (fr) 2004-03-12 2015-07-29 Alnylam Pharmaceuticals Inc. Agents iRNA ciblant VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (fr) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methodes de traitement des pathologies oculaires
CA2584502A1 (fr) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides et leur utilisation comme produits pharmaceutiques
WO2006020768A2 (fr) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Oligonucleotides chimiquement modifies
HRP20171010T8 (hr) * 2004-08-23 2017-11-03 Sylentis S.A.U. Liječenje poremećaja očiju koji su karakterizirani povišenim intraokularnim pritiskom pomoću sirnk
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
EP1856259A1 (fr) 2005-03-11 2007-11-21 Alcon Inc. Inhibition de la proteine-1 apparentee a frizzled induite par l'arni pour le traitement du glaucome

Also Published As

Publication number Publication date
CA2627272A1 (fr) 2007-05-03
ES2403305T3 (es) 2013-05-17
AU2006307690A1 (en) 2007-05-03
EP2354229A2 (fr) 2011-08-10
JP5398262B2 (ja) 2014-01-29
RU2008120702A (ru) 2009-12-10
EP2354229A3 (fr) 2012-12-05
JP2013176395A (ja) 2013-09-09
AU2006307690B2 (en) 2012-07-12
JP2009513617A (ja) 2009-04-02
MX2008005409A (es) 2008-11-26
WO2007049074A2 (fr) 2007-05-03
CN101346467B (zh) 2013-03-13
US8188057B2 (en) 2012-05-29
RU2420582C2 (ru) 2011-06-10
HK1120830A1 (en) 2009-04-09
US20110160277A1 (en) 2011-06-30
EP1941037A2 (fr) 2008-07-09
CN101346467A (zh) 2009-01-14
WO2007049074A3 (fr) 2007-08-02
GB0521716D0 (en) 2005-11-30
CA2627272C (fr) 2015-12-01
EP1941037B1 (fr) 2013-01-16

Similar Documents

Publication Publication Date Title
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
TW200637866A (en) Amino-imidazolones for the inhibition of β-secretase
TW200640924A (en) VEGF-R2 inhibitors and methods
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
WO2007092622A3 (fr) Compositions et méthodes pour le traitement d'os
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
SG161310A1 (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
EP4242655A3 (fr) Procédés et compositions pour le traitement du cancer et d'infections pérsistantes en inhibant la voie de la mort céllulaire programmée (pd-1)
MX2009013199A (es) Anticuerpos anti-notch1 nnr y sus metodos de uso.
WO2007038610A3 (fr) Utilisation de produits naturels pour le traitement de troubles neurologiques
ZA200802848B (en) Potassium channel inhibitors
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
WO2010053573A3 (fr) Criblage d'inhibiteurs de filovirus et leurs utilisations
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2008073332A3 (fr) Compositions de créatine pour traitement cutané
WO2007026251A3 (fr) Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
UA86119C2 (ru) Амидные пролекарства гемцитабина, их композиции и применение
TW200724140A (en) Hydantoin compounds
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
IN2015DN03331A (fr)
UA96265C2 (ru) Композиция и способ ингибирования jak пути передачи сигнала
WO2004060878A3 (fr) Inhibiteurs de phosphatases
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof